DeepMed Research

Ludwig Institut für Krebsforschung AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen

Phase 1

Completed

Conditions: Transitional Cell Carcinoma
Head and Neck Cancer
Esophageal Cancer
Gastrointestinal Stromal Tumor (GIST)
Prostate Cancer
Sarcoma
Ovarian Carcinoma
Melanoma
Breast Cancer

Interventions: Biological: Mixed bacterial vaccine

First Posted Date: 2008-02-26

Last Posted Date: 2022-10-25

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 17

Registration Number: NCT00623831

Locations: 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Primary Peritoneal Cancer
Epithelial Ovarian Cancer

Interventions: Biological: NY-ESO-1 OLP4 + Montanide
Biological: NY-ESO-1 OLP4
Biological: NY-ESO-1 OLP4 + Montanide + Poly-ICLC

First Posted Date: 2008-02-15

Last Posted Date: 2022-10-12

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 28

Registration Number: NCT00616941

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Phase 1

Terminated

Conditions: Renal Cell Carcinoma (RCC)

Interventions: Biological: Chimeric monoclonal antibody cG250
Drug: Sunitinib malate

First Posted Date: 2007-08-24

Last Posted Date: 2022-10-12

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 8

Registration Number: NCT00520533

Locations: 🇦🇺
Austin Health (Ludwig Institute Oncology Unit), Heidelberg, Victoria, Australia

Study of ADI-PEG 20 in Patients With Advanced Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma
Skin Cancer
Neoplasm

Interventions: Drug: ADI PEG 20

First Posted Date: 2007-08-24

Last Posted Date: 2022-10-25

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 31

Registration Number: NCT00520299

Locations: 🇺🇸
NYU Cancer Institute, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Biological: NY-ESO-1 ISCOMATRIX® vaccine
Drug: Cyclophosphamide

First Posted Date: 2007-08-20

Last Posted Date: 2022-10-25

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 46

Registration Number: NCT00518206

Locations: 🇦🇺
Austin Health (Ludwig Institute Oncology Unit), Heidelberg, Victoria, Australia
🇦🇺
Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia

NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

Phase 1

Completed

Conditions: Tumors

Interventions: Biological: NY-ESO-1 Protein Vaccine

First Posted Date: 2006-03-07

Last Posted Date: 2022-10-10

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 22

Registration Number: NCT00299728

Locations: 🇺🇸
NYU Clinical Cancer Center, New York, New York, United States
🇺🇸
NY Presbyterian- Columbia, New York, New York, United States

Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: 111-Indium-CMD-193
Drug: CMD-193

First Posted Date: 2006-02-17

Last Posted Date: 2022-10-10

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 9

Registration Number: NCT00293215

Locations: 🇦🇺
Cancer Care Services, Dept. of Medical Oncology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺
Ludwig Institute Tumor Targeting Program, Austin Health, Heidelberg (Melbourne), Victoria, Australia

Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Biological: NY-ESO-1 protein/CpG 7909

First Posted Date: 2006-02-15

Last Posted Date: 2023-10-04

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 15

Registration Number: NCT00292045

Locations: 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇨🇭
Universitätsspital Zürich, Zurich, Switzerland

111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen

Phase 1

Completed

Conditions: Neoplasms

Interventions: Biological: ch806

First Posted Date: 2006-02-14

Last Posted Date: 2022-10-10

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 8

Registration Number: NCT00291447

Locations: 🇦🇺
Ludwig Institute Tumor Targeting Program, Austin Health, Heidelberg, Victoria, Australia

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

Phase 1

Completed

Conditions: Esophageal Cancer
Lung Cancer
Stomach Cancer
Breast Cancer
Ovarian Cancer

First Posted Date: 2006-02-14

Last Posted Date: 2009-03-03

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 9

Registration Number: NCT00291473

Locations: 🇯🇵
Mie University Hospital, Tsu, Mie, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy